NRx-101 is the first investigational drug in FDA trials for suicidal bipolar depression, awarded fast track designation, breakthrough therapy designation.
NRx-101 is the first investigational drug in FDA trials for suicidal bipolar depression, awarded fast track designation, breakthrough therapy designation.
